Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections

Journal of Virology

Volumn 71, Issue 10, 1997, Pages 7799-7803

  Carr, J A ^a   Rogerson, J ^a   Mulqueen, M J ^a   Roberts, N A ^a   Booth, R F G ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HERPES VIRUS INFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 0030801240     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.10.7799-7803.1997     Document Type: Article

References (30)

1. Bi, Z., P. Quandt, T. Komatsu, M. Barna, and C. S. Reiss. 1995. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J. Immunol. 155:5684-5689.
2. Cavanaugh, V. J., L. G. Guidotti, and F. V. Chisari. 1997. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71:3236
3. Chehimi, J., S. E. Star, I. Frank, M. Rengaraju, S. J. Jackson, C. Lianes, M. Kobayashi, B. Perussia, D. Young, E. Nickbarg, S. F. Wolf, and G. Trinchieri. 1992. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J. Exp. Med. 175:789-796.
4. Chehimi, J., S. E. Starr, I. Frank, A. D'Andrea, X. Ma, R. R. MacGregor, J. Sennelier, and G. Trinchicri. 1994. Impaired interleukin 12 production in human immunodeficiency virus infected patients. J. Exp. Med. 179:1361-1366.
5. Chehimi, J., N. M. Valiante, A. D'Andrea, Z. Rosado, M. Kobayashi, B. Perussia, S. F. Wolf, S. E. Star, and G. Trinchieri. 1993. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol. 23:1826-1830.
6. Chougnet, C., T. A. Wynn, M. Clerici, A. L. Landay, H. A. Kessler, J. Rusnak, G. P. Melcher, A. Sher, and G. M. Shearer. 1996. Molecular analysis of decreased interleukin 12 production in persons infected with human immunodeficiency virus. J. Infect. Dis. 174:46-53.
7. Coutelier, J.-P., J. Van Broeck, and S. F. Wolf. 1995. Interleukin-12 gene expression after viral infection in the mouse. J. Virol. 69:1955-1958.
8. h2 cells. Eur. J. Immunol. 23:1762-1770.
9. Ho, M. 1991. Murinc cytomegalovirus, p. 327-353. In Cytomegalovirus: biology and infection, 2nd ed. Plenum Medical Book Co., New York, N.Y.
10. Iwasaka, T., J. F. Sheridan, and L. Aurelian. 1983. Immunity to herpes simplex virus type 2: recurrent lesions are associated with the induction of suppressor cells and soluble suppressor factors. Infect. Immun. 42:955-964.
11. Jonjic, S., I. Pavic, B. Polic, I. Crnkovic, P. Lucin, and U. H. Koszinowski. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179:1713-1717.
12. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827-845.
13. Matsuo, R., M. Kobayashi, D. N. Herndon, R. B. Pollard, and F. Suzuki. 1996. Interleukin 12 protects thermally injured mice from herpes simplex virus type 1 infection. J. Leukocyte Biol. 59:623-630.
14. McKendall, R. R. 1983. Delayed IgG-mediated clearance of herpes simplex virus type 1 from the CNS but not the footpad during the early stages of infection: possible result of relative integrity of the blood-brain barrier. J. Gen. Virol. 64:1965-1972.
15. Milich, D. R., S. F. Wolf, J. L. Hughes, and J. E. Jones. 1995. Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proc. Natl. Acad. Sci. USA 92:6847-6851.
16. Murray, H. W., and J. Hariprashad. 1995. Interleukin-12 is effective treatment for an established systemic intraccllular infection: experimental visceral leishmaniasis. J. Exp. Med. 181:387-391.
17. Nash, A. A., H. J. Field, and R. Quartey-Papafio. 1980. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity. J. Gen. Virol, 48:351-357.
18. Oakes, J. E. 1975. Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect. Immun. 12:166-172.
19. Orange, J. S., and C. A. Biron. 1996. An absolute and restricted requirement for IL-12 in natural killer cell IFN γ production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J. Immunol. 156:1138-1142.
20. Orange, J. S., S. F. Wolf, and C. A. Biron. 1994. Effects of IL-12 in the response and susceptibility to experimental viral infections. J. Immunol. 152:1253-1264.
21. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwen, and C. A. Biron, 1995. Mechanism of interleukin-12 mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181:901-914.
22. Ozmen, L., M. Aguet, G. Trinchieri, and G. Garotta. 1995. The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon. J. Virol. 69:8147-8150.
23. Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35:1-39.
24. Tang, V. W., and B. S. Graham. 1995. Interleukin 12 treatment during immunization elicits a T helper cell type 1 like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J. Infect. Dis. 172:734-738.
25. Taylor, J. L., P. Tom, J. Guy, R. M. Selvarajan, and W. J. O'Brien. 1994. Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of alpha interferon and acyclovir. Antimicrob. Agents Chemother. 38:853-856.
26. Than, S., R. Hu, N. Oyaizu, J. Romano, X. Wang, S. Sheikh, and S. Pahwa. 1997. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J. Infect. Dis. 175:47-56.
27. Wuchsman, M., J. H. Luo, L. Aurelian, and E. Paoletti. 1992. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D. Vaccine 10:447-454.
28. Wolf, S. F., P. A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Löwe, R. Dzialo, L. Fitz, C. Ferenz, R. M. Hewick, K. Kelleher, S. H. Herrmann, S. C. Clark, L. Azzoni, S. H. Chan, G. Trinchieri, and B. Perussia. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146:3074-3081.
29. Wolf, S. F., D. Sieburth, and J. Sypek. 1994. Interleukin 12: a key modulator of immune function. Stem Cells 12:154-164.
30. Yoo, J., H. Chen, T. Kraus, D. Hirsch, S. Polyak, I. George, and K. Sperber. 1996. Altered cytokine production and accessory cell function after HIV-1 infection. J. Immunol. 157:1313-1320.